Dialysis vintage, not age, predicted RSV vaccine response

Design

Observational immunogenicity study with matched controls

Population

20 patients receiving haemodialysis (median age 78.4 years, median dialysis duration 23 months) and 15 age- and sex-matched controls with normal kidney function

Primary outcome

RSV-specific IgG and cellular responses to week 32 after a single Arexvy dose

Effect

IgG flat to week 5, significant rise at week 8 (16.8 SU), peak at week 16 (17.5 SU) from 12.6 SU baseline; controls rising by week 2; titres inversely related to dialysis duration

Patients on haemodialysis are older, immunologically impaired and repeatedly exposed to healthcare settings, which makes them a priority group for RSV vaccination and a group in whom vaccine immunogenicity data barely exist. This observational study, published in June, gave a single dose of Arexvy to 20 haemodialysis patients (median age 78.4 years, median dialysis duration 23 months) and compared them with 15 age- and sex-matched controls with normal kidney function.

The response came, but late. IgG was flat through week five, rose significantly by week eight, peaked at week 16 and was still above baseline at week 32. Matched controls were already rising at two weeks. RSV-specific CD4 T cells increased at week two, mostly producing IFN-γ, IL-2 or TNF, and returned to baseline by week eight; plasmablasts expanded at weeks five to eight.

The finding with practical weight is that antibody levels correlated negatively with dialysis duration, and patients dialysing for under a year had significantly higher titres. That points at accumulated uraemic immune dysfunction rather than age as the determinant — and it argues for vaccinating early in a dialysis career rather than when the season arrives.

• Vaccinate against RSV early in the dialysis course rather than deferring; response falls with dialysis vintage.
• Give the vaccine well before the RSV season — protection in this group is unlikely to be established before about eight weeks.
• Do not treat a post-vaccination titre at two or four weeks as a failure; the response in these patients is delayed rather than absent.
• Apply the same timing logic to other vaccines in long-vintage dialysis patients.
• Twenty patients is a very small study; the timing signal is more useful than any absolute titre it reports.

Why it matters

A vaccine given a fortnight before the season may be doing nothing at all for a long-vintage dialysis patient.

Don't overread it

This measured antibody and T-cell responses in 20 people, not RSV infections or hospitalisations.

The statistics, in plain English

With 20 patients and 15 controls, this study can describe the shape of a response curve and cannot estimate protection. The negative correlation between antibody level and dialysis duration comes from within those 20 patients, so it is a hypothesis rather than an established determinant. Antibody titre is also a surrogate: no RSV infections were counted, and the titre threshold that confers protection in this population is not known.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.